A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 177, Issue 1, 1998, Pages 231-234

  Bartlett, John A ^a   Berry, Paul S ^b   Bockman, K Wayne ^b   Stein, Allan ^b   Johnson, Judy ^b   Graham, Shannon ^b   Quinn, Joseph ^b   DeMasi, Ralph ^b   James Alexander, W ^b  

^a DUKE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RANITIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031984934     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517361     Document Type: Article

References (15)

1. Pantaleo G, Graziosi C, Demarest J, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;363:355-8.
2. Embretson J, Zupancic M, Ribas J, et al. Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
3. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir, zidovudine and lamivudine [abstract Th.B.931]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
4. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
5. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91; erratum, 1996;348:834; comments, 1996;348:278-9, 1996;348:1238-9.
6. + T-cell repertoire that are not immediately restored by antiretroviral or immune-based therapies. Nature Med 1997;3:533-40.
7. Rocklin R. Modulation of cellular-immune responses in vivo and in vitro by histamine-bearing lymphocytes. J Clin Invest 1976;57: 1051-8.
8. Damle N, Gupta S. Autologous mixed lymphocyte reaction in man. II. Histamine-induced suppression of the autologous mixed lymphocyte reaction by T-cell subsets defined with monoclonal antibodies. J Clin Immunol 1981;1:241-9.
9. 2-receptor antagonists on delayed hypcrsensitivity. Lancet 1978;1:624-6.
10. Jorizzo J, Sams W, Jegasothy B, Olansky A. Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model. Ann Intern Med 1980;92:192-5.
11. Allen J, Syropoulos H, Grant B, Eagon C, Kay N. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. J Lab Clin Med 1987;109:396-401.
12. Brockmeyer N, Kreuzfelder E, Mertins L, et al. Immunomodulatory properties of cimetidine in ARC patients. Clin Immunol Immunopathol 1988; 48:50-60.
13. Nielson H, Svenningsen A, Moesgaard F, et al. Ranitidine improves certain cellular immune responses in asymptomatic HIV-infected individuals. J Acquir Immune Defic Syndr 1991;4:577-84.
14. Cohen CJ, Hellinger JA, Day J, et al. Lack of effect of cimetidine on lymphocyte subsets in patients infected with human immunodeficiency virus type 1. Clin Infect Dis 1996;23:1049-54.
15. Dawson JD. Comparing treatment groups on the basis of slopes, areas under-the-curve, and other summary measures. Drug Info J 1994;28: 723-32.